bioAffinity Technologies (BIAF) Operating Leases (2023 - 2026)

bioAffinity Technologies has disclosed Operating Leases across 4 years of filings, most recently posting $687460.0 for Q1 2026.

• In Q1 2026, Operating Leases rose 122.9% year-over-year to $687460.0; the TTM figure through Mar 2026 stood at $687460.0 (up 122.9% YoY), while the FY2025 annual figure was $202878.0, down 40.7% from the prior year.
• Operating Leases improved to $687460.0 in Q1 2026, from $202878.0 in the prior quarter.
• Over the last five years, Operating Leases for BIAF reached as high as $687460.0 in Q1 2026 and fell as low as $202878.0 in Q4 2025.
• The 4-year median for Operating Leases is $331307.0 (2024), against an average of $363906.1.
• Annual changes were most pronounced in 2025 — Operating Leases tumbled 40.7% — and 2026, when it surged 122.9%.
• A 4-year view of Operating Leases shows it stood at $283001.0 in 2023, then climbed by 20.88% to $342098.0 in 2024, then plunged by 40.7% to $202878.0 in 2025, then jumped by 238.85% to $687460.0 in 2026.
• According to Business Quant data, Operating Leases over the past three periods registered $687460.0, $202878.0, and $375139.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.